Business
Voyageur Pharmaceuticals Ltd. Announces Two Health Canada Approvals and Issuance of Product Licenses for MultiX Ba; Radiographic Barium Contrast
(TheNewswire) Calgary, Alberta - TheNewswire - April 5 ...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Ltd. Announces Two Health Canada Approvals and Issuance of Product Licenses for MultiX Ba; Radiographic Barium Contrast\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, Alberta -\n \n \n TheNewswire\n-\n \n \n April 5\n \n \n th\n \n \n , 2021 -\nVoyageur Pharmaceuticals Ltd. (\n \n \n TSX.V:VM)\n \n \n (\n \n \n OTC\n \n \n :VYYRF\n \n \n ) (the \"Company\" or\n\"Voyageur\") is pleased to announce that it has received\napproval from Health Canada (HC) for its product, MultiX barium\nsulfate powder. MultiX is specifically designed\n \n \n \n for oral\nsuspension and indicated for use in single contrast radiographic\nexaminations of the esophagus, stomach, duodenum and small bowel to\nvisualize the gastrointestinal tract in adult and pediatric patients.\nVoyageur received 2 licenses for MultiX, one license for oral\napplications and one license for rectal applications.\n \n \n \n \n \n Voyageur is building a suite of barium radiographic\ncontrast media products and is working with our custom manufacturer,\nAlberta Veterinarian Laboratories (AVL), which company owns and\noperates a brand new, multi-million dollar, state-of-the-art, Good\nManufacturing Practice (GMP) drug manufacturing facility in Calgary,\nAlberta, Canada. Voyageur is rapidly moving to launch its sales into\nthe Canadian and international market places.\n \n \n \n \n With three drugs\nnow approved and licensed by Health Canada and two more in the offing,\nVoyageur is shortly hiring highly-experienced\n \n \n radiographic contrast media professionals to our team to\nsupport:\n \n \n \n \n \n \n -\n \n \n Scientific research and\ndevelopment to capitalize on opportunities to expand our high-quality\nbarium and iodine contrast product portfolio into global\nmarkets.\n \n \n \n \n - International marketing, sales and\ndistribution.\n \n \n \n \n \n \n Marketing and Sales Strategy\n2021\n \n \n \n \n Approval timelines and high profit margin are the\ncriteria for Voyageur’s international sales strategy. Voyageur is\nactively analyzing international markets, where recognition of\nVoyageur's Health Canada registrations is anticipated to assist\nVoyageur in obtaining licenses in an expeditious manner. Upon\nconclusion of our analysis, Voyageur will begin applying for\nregistration applications on a country...